Risk Factors of Cardiovascular Death after Venous Thromboembolism: Results from a Prospective Cohort Study

Steve Raoul Noumegni; Vincent Mansourati; Cécile Tromeur; Raphael Le Mao; Clément Hoffmann; Emmanuelle Le Moigne; Bahaa Nasr; Jean-Christophe Gentric; Marie Guegan; Elise Poulhazan; Luc Bressollette; Karine Lacut; Francis Couturaud; Romain Didier

doi:10.1055/s-0042-1748889

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2022; 122(10): 1744-1756
DOI: 10.1055/s-0042-1748889

Stroke, Systemic or Venous Thromboembolism

Risk Factors of Cardiovascular Death after Venous Thromboembolism: Results from a Prospective Cohort Study

Authors

Steve Raoul Noumegni

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Vincent Mansourati

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

³Department of Cardiology, Brest Teaching Hospital, Brest, France
Cécile Tromeur

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Raphael Le Mao

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Clément Hoffmann

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Emmanuelle Le Moigne

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Bahaa Nasr

⁴Department of Vascular Surgery, Brest Teaching Hospital, Brest, France
Jean-Christophe Gentric

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France

⁵Department of Neuroradiology, Brest Teaching Hospital, Brest, France
Marie Guegan

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Elise Poulhazan

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Luc Bressollette

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Karine Lacut

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Francis Couturaud

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

²Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
Romain Didier

¹Department of Internal Medicine, Vascular Medicine and Pneumology, Brest Teaching Hospital, Brest, France

³Department of Cardiology, Brest Teaching Hospital, Brest, France

Abstract

Background Cardiovascular deaths (CVDTs) are more frequent in patients with venous thromboembolism (VTE) than in the general population; however, risk factors associated with this increased risk of CVDT in patients with VTE are not described.

Methods To determine the risk factors of CVDT in patients with VTE from a multicenter prospective cohort study, Fine and Gray subdistribution hazard models were conducted.

Results Of the 3,988 included patients, 426 (10.7%) died of CVDT during a median follow-up of 5 years. The risk factors of CVDT after multivariate analyses were: age of 50 to 65 years (vs. <50 years, hazard ratio [HR]: 3.22, 95% confidence interval [CI]: 1.67–6.62), age >65 years (vs. <50 years, HR: 7.60, 95% CI: 3.73–15.52), cancer-associated VTE (vs. transient risk factor-related VTE, HR: 1.73, 95% CI: 1.15–2.61), unprovoked VTE (vs. transient risk factor-related VTE, HR: 1.42, 95% CI: 1.02–2.00), past tobacco use (vs. never, HR: 1.43, 95% CI: 1.06–1.94), current tobacco use (vs. never, HR: 1.87, 95% CI: 1.15–3.01), hypertension (HR: 2.11, 95% CI: 1.51–2.96), chronic heart failure (HR: 2.28, 95% CI: 1.37–3.79), chronic respiratory failure (HR: 1.72, 95% CI: 1.02–2.89), and atrial fibrillation (HR: 1.67, 95% CI: 1.06–2.60). The risk of CVDT was significantly reduced with direct oral anticoagulants (vs. vitamin-K antagonists) and with longer duration of treatment (>3 months).

Conclusion Risk factors of CVDT after VTE include some traditional cardiovascular risk factors and other risk factors that are related to characteristics of VTE, and patients' comorbidities.

Keywords

venous thromboembolism - cardiovascular deaths - cardiovascular mortality - risk factors - predictor - prospective cohort

Volltext

Referenzen

References
1 WHO. Cardiovascular diseases (CVDs) [Internet]. Accessed September 30, 2021 at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2 Gregson J, Kaptoge S, Bolton T. et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4 (02) 163-173
3 Noumegni SR, Hoffmann C, Tromeur C. et al. Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: a systematic review and meta-analysis of cohort studies. Thromb Res 2021; 203: 172-185
4 Adelborg K, Sundbøll J, Sørensen HT. Arterial cardiovascular events and mortality following venous thromboembolism. Ann Transl Med 2015; 3 (09) 117
5 Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Calvo-Rojas G, Vargas-Castrillón E. Causes of death in patients with venous thromboembolism anticoagulated with direct oral anticoagulants: a systematic review and meta-analysis. Semin Thromb Hemost 2018; 44 (04) 377-387
6 Ng ACC, Chung T, Yong ASC. et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011; 4 (01) 122-128
7 Brenner B, Bikdeli B, Tzoran I. et al; RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism. Am J Med 2018; 131 (09) 1095-1103
8 Becattini C, Agnelli G, Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26 (01) 77-83
9 Noumegni SR, Grangereau T, Demir A, Bressollette L, Couturaud F, Hoffmann C. Cardiovascular mortality after venous thromboembolism: a meta-analysis of prospective cohort studies. Semin Thromb Hemost 2021
10 Huerta C, Johansson S, Wallander M-A, Rodríguez LAG. Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism. Thromb J 2008; 6: 10
11 Roach REJ, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC. Increased risk of CVD after VT is determined by common etiologic factors. Blood 2013; 121 (24) 4948-4954
12 Golemi I, Cote L, Iftikhar O. et al; Registro Informatizado de Enfermedad Tromboembólica Investigators. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. J Vasc Surg Venous Lymphat Disord 2020; 8 (03) 353-359.e1
13 Bilora F, Ceresa M, Milan M, Sarolo L, Prandoni P. The impact of deep vein thrombosis on the risk of subsequent cardiovascular events: a 14-year follow-up study. Int Angiol 2017; 36 (02) 156-159
14 Chang W-T, Chang C-L, Ho C-H, Hong C-S, Wang J-J, Chen Z-C. Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events. J Am Heart Assoc 2017; 6 (05) e005466
15 Cannegieter SC, Horváth-Puhó E, Schmidt M. et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood 2015; 125 (02) 229-235
16 Tromeur C, Sanchez O, Presles E. et al; PADIS-PE Investigators18. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. Eur Respir J 2018; 51 (01) 1701202
17 Nemeth B, Lijfering WM, Nelissen RGHH. et al. Risk and risk factors associated with recurrent venous thromboembolism following surgery in patients with history of venous thromboembolism. JAMA Netw Open 2019; 2 (05) e193690
18 Oger E, Lacut K, Le Gal G. et al; EDITH COLLABORATIVE STUDY GROUP. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006; 4 (04) 793-799
19 Le Moigne E, Tromeur C, Delluc A. et al. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study. Haematologica 2016; 101 (01) e12-e14
20 Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128 (08) 663-677
21 Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359 (26) 2804-2813
22 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii , 1–253
23 Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJG. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009; 20 (07) 722-727
24 Hicks KA, Mahaffey KW, Mehran R. et al; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 2018; 71 (09) 1021-1034
25 Hicks KA, Tcheng JE, Bozkurt B. et al; ACC/AHA TASK FORCE ON CLINICAL DATA STANDARDS MEMBERS. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol 2015; 22 (05) 1041-1144
26 Stegherr R, Schmoor C, Lübbert M, Friede T, Beyersmann J. Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. Pharm Stat 2021; 20 (06) 1125-1146
27 Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16 (03) 1141-1154
28 Chuang L-H, Gumbs P, van Hout B. et al. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Qual Life Res 2019; 28 (08) 2111-2124
29 Monreal M, Agnelli G, Chuang LH. et al. Deep vein thrombosis in Europe-health-related quality of life and mortality. Clin Appl Thromb Hemost 2019; 25: 1076029619883946
30 Ģībietis V, Kigitoviča D, Vītola B, Strautmane S, Skride A. Glomerular filtration rate as a prognostic factor for long-term mortality after acute pulmonary embolism. Med Princ Pract 2019; 28 (03) 264-272
31 Faller N, Limacher A, Méan M. et al. Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med 2017; 130 (02) 198-206
32 Huerta C, Johansson S, Wallander M-A, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167 (09) 935-943
33 Laliberté F, Nutescu EA, Lefebvre P. et al. Risk factors associated with myocardial infarction in venous thromboembolism patients. Curr Med Res Opin 2014; 30 (01) 27-35
34 Ljungqvist M, Holmström M, Kieler H, Odeberg J, Lärfars G. Cardiovascular disease and mortality after a first episode of venous thromboembolism in young and middle-aged women. Thromb Res 2016; 138: 80-85
35 Madridano O, del Toro J, Lorenzo A. et al; RIETE Investigators. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg Venous Lymphat Disord 2015; 3 (02) 135-41.e1
36 Mahoney MC, Rivard C, Hammad HT. et al. Cardiovascular risk factor and disease measures from the Population Assessment of Tobacco and Health (PATH) study. Int J Environ Res Public Health 2021; 18 (14) 7692
37 Johansson I, Joseph P, Balasubramanian K. et al; G-CHF Investigators. Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation 2021; 143 (22) 2129-2142
38 Go AS, Reynolds K, Yang J. et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM Study. JAMA Cardiol 2018; 3 (07) 601-608
39 Lutsey PL, Norby FL, Alonso A. et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J Thromb Haemost 2018; 16 (04) 670-679
40 Tang L, Wu Y-Y, Lip GYH, Yin P, Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2016; 3 (01) e30-e44
41 Han KH, O'Neill WC. Increased peripheral arterial calcification in patients receiving warfarin. J Am Heart Assoc 2016; 5 (01) e002665